Wyeth R&D Shifts Focus To New Products, Away From Lifecycle Management
Executive Summary
Wyeth is shifting R&D spending away from lifecycle management, Exec VP-Pharmaceutical R&D Robert Ruffolor said
You may also be interested in...
Wyeth Says Portfolio Growth Potential Separates It From Other Big Pharmas
Wyeth expects new products to provide incremental growth, rather than replace lost revenue, given the remaining growth potential for its marketed products, President Bernard Poussot said Oct. 5
Wyeth Says Portfolio Growth Potential Separates It From Other Big Pharmas
Wyeth expects new products to provide incremental growth, rather than replace lost revenue, given the remaining growth potential for its marketed products, President Bernard Poussot said Oct. 5
Wyeth R&D Pipeline Is 75% NMEs; Two Launches Per Year Will Start In 2006
Three-quarters of the projects in Wyeth's research and development pipeline are new molecular entities, Wyeth Research President Robert Ruffolo, PhD, said during the company's R&D day in New York June 2